Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia

Seminars in Oncology

Volumn 30, Issue 2, 2003, Pages 282-285

  Munshi, N C ^a,b   Barlogie, B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERFERON; MELPHALAN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ARTICLE; BONE MARROW PURGING; BONE MARROW RESCUE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL DESTRUCTION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; STEM CELL MOBILIZATION; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

EID: 0037397380     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50080     Document Type: Article

References (15)

1. Waldenstrom JG: Macroglobulinemia - A review. Haematologica 71:437-440, 1986
2. Dimopoulos MA, Alexanian R: Waldenstrom's macroglobulinemia. Blood 83:1452-1459, 1994
3. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000
4. Munshi NC, Tricot T, Barlogie BB: Plasma cell neoplasms, in DeVita V Jr, Rosenberg SA, Hellman S (eds): Principles and Practice of Oncology (ed 6). New York, NY, Lippincott-Raven, 2000, pp 2349-2412
5. Desikan R, Barlogie B, Sawyer J, et al: Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008-4010, 2000
6. Attal M, Harousseau JL, Stoppa AM, et al: Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma: A prospective, randomized trial. N Engl J Med 335:91-97, 1996
7. Harousseau J-L, Attal M: The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 34:61-66, 1997
8. Desikan R, Dhodapkar M, Siegel D, et al: High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 105:993-996, 1999
9. Rudnicki SA, Harik SI, Dhodapkar M, et al: Nervous system dysfunction in Waldenstrom's macroglobulinemia: Response to treatment. Neurology 51:1210-1213, 1998
10. Dreger P, Glass B, Kuse R, et al: Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 106:115-118, 1999
11. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
12. Mazza P, Palazzo G, Amurri B, et al: Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: An interim report. Bone Marrow Transplant 23:1273-1278, 1999
13. Yang L, Wen B, Li H, et al: Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia. Bone Marrow Transplant 24:929-930, 1999
14. Anagnostopoulos A, Dimopoulos MA, Aleman A, et al: High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 27:1027-1029, 2001
15. Mustafa M, Powles R, Treleaven J, et al: Total therapy with VAMP/CVAMP + high dose melphalan and autograft for IgM lymphoplasmacytoid disease. Blood 92:281b, 1998